1. Home
  2. CAPR vs SHBI Comparison

CAPR vs SHBI Comparison

Compare CAPR & SHBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • SHBI
  • Stock Information
  • Founded
  • CAPR 2005
  • SHBI 1876
  • Country
  • CAPR United States
  • SHBI United States
  • Employees
  • CAPR N/A
  • SHBI N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • SHBI Major Banks
  • Sector
  • CAPR Health Care
  • SHBI Finance
  • Exchange
  • CAPR Nasdaq
  • SHBI Nasdaq
  • Market Cap
  • CAPR 453.9M
  • SHBI 415.6M
  • IPO Year
  • CAPR N/A
  • SHBI N/A
  • Fundamental
  • Price
  • CAPR $11.66
  • SHBI $16.71
  • Analyst Decision
  • CAPR Strong Buy
  • SHBI Buy
  • Analyst Count
  • CAPR 8
  • SHBI 2
  • Target Price
  • CAPR $33.75
  • SHBI $20.00
  • AVG Volume (30 Days)
  • CAPR 3.0M
  • SHBI 217.9K
  • Earning Date
  • CAPR 08-06-2025
  • SHBI 07-24-2025
  • Dividend Yield
  • CAPR N/A
  • SHBI 2.87%
  • EPS Growth
  • CAPR N/A
  • SHBI 241.50
  • EPS
  • CAPR N/A
  • SHBI 1.48
  • Revenue
  • CAPR $17,363,588.00
  • SHBI $201,667,000.00
  • Revenue This Year
  • CAPR $258.96
  • SHBI $6.10
  • Revenue Next Year
  • CAPR $8.02
  • SHBI $7.16
  • P/E Ratio
  • CAPR N/A
  • SHBI $11.29
  • Revenue Growth
  • CAPR N/A
  • SHBI 37.93
  • 52 Week Low
  • CAPR $3.52
  • SHBI $11.15
  • 52 Week High
  • CAPR $23.40
  • SHBI $17.61
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 50.35
  • SHBI 76.78
  • Support Level
  • CAPR $9.65
  • SHBI $14.35
  • Resistance Level
  • CAPR $10.56
  • SHBI $16.98
  • Average True Range (ATR)
  • CAPR 1.21
  • SHBI 0.34
  • MACD
  • CAPR -0.02
  • SHBI 0.15
  • Stochastic Oscillator
  • CAPR 70.08
  • SHBI 94.68

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About SHBI Shore Bancshares Inc

Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in two business segments - community banking and mortgage banking. Community banking is conducted through the Bank and involves delivering a broad range of financial services, including lending and deposit-taking, to individuals and commercial enterprises, it also includes treasury and administrative functions. Mortgage banking is conducted through the Bank's secondary marketing department and involves originating first and second-lien residential mortgages for sale in the secondary market.

Share on Social Networks: